Background
Methods
Patients
Tissue microarray and immunohistochemistry
Quantification of TIL
Statistical Analysis
Results
Study group
N (%) | ||
---|---|---|
Factor | All patients | 52 (100) |
Gender | Male | 40 (76.9) |
Female | 12 (23.1) | |
TNM stage (UICC 2002) | I | 20 (39.2) |
II | 19 (36.5) | |
III | 10 (19.2) | |
IV | 3 (5.8) | |
Grading | G 1 | 1 (2) |
G 2 | 29 (56) | |
G 3 | 21 (40) | |
G 4 | 1 (2) | |
T category | T 1 | 12 (23) |
T 2 | 32 (62) | |
T 3 | 5 (10) | |
T 4 | 3 (6) | |
N category | N 0 | 24 (46.2) |
N + | 28 (53.8) | |
N 1 | 22 (42.3) | |
N 2 | 6 (11.5) | |
Any Relapse | Yes | 17 (32.7) |
No | 35 (67.3) | |
Local recurrence | Yes | 5 (9.6) |
No | 47 (90.4) | |
Distant Metastasis | Yes | 14 (26.9) |
No | 38 (73.1) | |
Status | Alive with NED | 25 (48) |
Dead of disease | 15 (29) | |
Dead without disease | 12 (23) |
Mean | Median | 95% C.I. | |
---|---|---|---|
Age (years) | 64.6 | 67.0 | 61.5 - 67.7 |
Follow-up time (months) | 71.2 | 61.0 | 54.7 - 57.8 |
Overall survival time (months) | 58.6 | 50.0 | 46.4 - 70.8 |
NED-survival time (months) | 55.7 | 41.5 | 43.1 - 68.3 |
Time to relapse (months) | 23.8 | 17.0 | 13.8 - 33.7 |
Distribution pattern of lymphocytes in gastric adenocarcinoma
Cells per mm2
| Mean | |||||
---|---|---|---|---|---|---|
Primary tumour | Metastatic lymph node | Uninvolved lymph node | ||||
epithelial | stromal | epithelial | stromal | lymphatic tissue | ||
CD3 | 122.8 | 895.7 | 63.5 | 645.1 | 3710.1 | 7686.7 |
CD8 | 114.5 | 424.4 | 98.0 | 358.2 | 1071.9 | 2436.1 |
CD20 | 18.9 | 438.7 | 9.4 | 351.4 | 5612.7 | n.d. |
CD68 | 18.7 | 482.7 | 17.9 | 617.1 | 1457.8 | 506.4 |
FoxP3 | 14.3 | 187.5 | 12.1 | 90.2 | 532.0 | 337.0 |
Gran.B | 3.0 | 39.8 | 0.8 | 42.3 | 89.4 | 46.9 |
Cells per mm
2
|
95% confidence interval of mean
| |||||
Primary tumour
|
Metastatic lymph node
|
Uninvolved lymph node
| ||||
epithelial
|
stromal
|
epithelial
|
stromal
|
lymphatic tissue
| ||
CD3 | 71.2 - 174.5 | 714.6 - 1076.8 | 3.7 - 123.3 | 389.4 - 900.9 | 3149.5 - 4270.7 | 7088.1 - 8285.4 |
CD8 | 51.1 - 178.0 | 299.6 - 549.2 | 0 (-35.3) - 231.3 | 146.2 - 570.3 | 696.9 - 1447.0 | 2203.2 - 2669.0 |
CD20 | 0 (-0.1) - 37.9 | 249.7 - 627.7 | 0 (-2.1) - 20.9 | 180.9 - 521.8 | 4800.7 - 6424.8 | n.d. |
CD68 | 12.5 - 24.9 | 407.6 - 557.7 | 2.2 - 33.6 | 388.6 - 845.6 | 1051.8 - 1863.9 | 451.5 - 561.4 |
FoxP3 | 6.5 - 22.2 | 142.0 - 233.0 | 5.7 - 18.5 | 51.5 - 128.8 | 179.3 - 884.7 | 256.2 - 417.7 |
Gran.B | 0.6 - 5.4 | 28.3 - 51.2 | 0 - 1.7 | 21.4 - 63.2 | 17.7 - 161.1 | 32.8 - 61.0 |
Cells per mm
2
|
Median
| |||||
Primary tumor
|
Metastatic lymph node
|
Uninvolved lymph node
| ||||
epithelial
|
stromal
|
epithelial
|
stromal
|
lymphatic tissue
| ||
CD3 | 40.9 | 752.1 | 18.3 | 366.2 | 3625.3 | 7752.0 |
CD8 | 21.6 | 212.7 | 2.8 | 203.7 | 888.5 | 2433.4 |
CD20 | 0 | 146.7 | 0 | 242.8 | 5855.7 | n.d. |
CD68 | 11.5 | 480.9 | 2.3 | 487.5 | 1238.8 | 478.6 |
FoxP3 | 3.6 | 125.9 | 8.0 | 75.6 | 225.7 | 245.4 |
Gran.B | 0 | 26.7 | 0 | 23.4 | 42.9 | 34.1 |
Prognostic significance of tumour infiltrating lymphocytes (TIL) and tumour infiltrating macrophages (TIM)
Univariate Analysis | Multivariate Analysis | |||||
---|---|---|---|---|---|---|
Variable | Hazard ratio | 95% C.I. | P | Hazard ratio | 95% C.I. | P |
Age, years (continuous) | 1.01 | 0.96-1.06 | 0.78 | - | - | - |
Gender (female [n = 12] vs male [n = 40]) | 0.48 | 0.11-2.10 | 0.33 | - | - | - |
Stage (UICC II and higher [n = 32] vs. UICC I [n = 20]) | 3.72 | 1.07-12.98 | 0.04 | 2.00 | 0.42-9.09 | 0.39 |
Grade (3+4 [n = 22] vs. 1+2 [n = 30]) | 1.43 | 0.55-3.71 | 0.46 | - | - | - |
T category (T3/T4 [n = 8] vs. T1/T2 [n = 44]) | 2.48 | 0.80-7.68 | 0.11 | - | - | - |
N category (. N+ [n = 28] vs N0 [n = 24]) | 3.27 | 1.06-10.02 | 0.04 | 2.04 | 0.51-8.33 | 0.32 |
Number of metastatic lymph nodes (continuous) | 1.35 | 1.17-1.56 | <0.001 | - | - | - |
TILs and macrophages in primary tumour site (high vs. low)
| ||||||
Hazard ratio
|
95% C.I. |
P
|
Hazard ratio
|
95% C.I. |
P
| |
Intraepithelial
| ||||||
CD3+ TIL | 0.76 | 0.29-1.98 | 0.58 | - | - | - |
CD8+ TIL | 1.26 | 0.48-3.32 | 0.63 | - | - | - |
CD20+ TIL | 2.05 | 0.79-5.32 | 0.14 | - | - | - |
CD68+ TIM | 0.69 | 0.27-1.80 | 0.45 | - | - | - |
FoxP3+ TIL | 0.78 | 0.30-2.03 | 0.61 | - | - | - |
Granzyme B+ TIL | 0.72 | 0.21-2.53 | 0.61 | - | - | - |
Stromal
| - | - | - | |||
CD3+ TIL | 0.86 | 0.33-2.23 | 0.76 | - | - | - |
CD8+ TIL | 0.85 | 0.33-2.20 | 0.74 | - | - | - |
CD20+ TIL | 0.80 | 0.31-2.08 | 0.65 | - | - | - |
CD68+ TIM | 0.81 | 0.31-2.10 | 0.66 | - | - | - |
FoxP3+ TIL | 0.23 | 0.08-0.72 |
0.01
| 0.25 | 0.08-0.78 |
0.016
|
Granzyme B+ TIL | 0.87 | 0.33-2.29 | 0.78 | - | - | - |
Ratio stromal CD68 (primary tumour)/stromal FoxP3 (primary tumour) | 4.02 | 1.31-12.36 |
0.02
| |||
TIL and macrophages in metastatic tissue (high vs. low)
| ||||||
Intraepithelial
|
Hazard ratio
|
95% C.I. |
P
| |||
CD3+ TIL | 0.32 | 0.09-1.12 | 0.07 | |||
CD8+ TIL | 1.14 | 0.35-3.76 | 0.83 | |||
CD20+ TIL | 0.20 | 0.03-1.58 | 0.13 | |||
CD68+ TIM | 0.96 | 0.29-3.16 | 0.95 | |||
FoxP3+ TIL | 0.58 | 0.17-1.99 | 0.39 | |||
Granzyme B+ TIL | 0.88 | 0.19-4.09 | 0.87 | |||
Stromal
| ||||||
CD3+ TIL | 0.61 | 0.19-2.03 | 0.42 | |||
CD8+ TIL | 1.16 | 0.35-3.81 | 0.81 | |||
CD20+ TIL | 0.51 | 0.15-1.75 | 0.28 | |||
CD68+ TIM | 1.30 | 0.40-4.28 | 0.66 | |||
FoxP3+ TIL | 0.81 | 0.25-2.69 | 0.74 | |||
Granzyme B+ TIL | 0.75 | 0.23-2.46 | 0.63 | |||
Lymphocytes and macrophages in uninvolved regional lymph node (high vs. low)
| ||||||
Hazard ratio
|
95% C.I. |
P
| ||||
CD3+ | 0.47 | 0.17-1.26 | 0.13 | |||
CD8+ | 0.84 | 0.32-2.19 | 0.72 | |||
CD20+ | ||||||
CD68+ | 0.56 | 0.21-1.47 | 0.24 | |||
FoxP3+ | 1.03 | 0.40-2.68 | 0.95 | |||
Granzyme B+ | 0.35 | 0.12-0.99 |
0.05
|